, Tracking Stock Market Picks
Enter Symbol:
Auxilium Pharmaceuticals, Inc. (AUXL) [hlAlert]

up 116.56 %

Auxilium Pharmaceuticals, Inc. (AUXL) upgraded to Buy with price target $23 by Collins Stewart

Posted on: Wednesday,  Oct 19, 2011  8:25 AM ET by Collins Stewart

Collins Stewart rated Buy Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) on 10/19/2011, when the stock price was $16.84. Since
then, Auxilium Pharmaceuticals, Inc. has gained 116.57% as of 01/29/2015's recent price of $36.47.
If you would have followed this Collins Stewart's recommendation on AUXL, you would have gained 116.56% of your investment in 1198 days.

Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets products for urology and sexual health. Auxilium markets Testim 1%, a topical testosterone gel, for the treatment of hypogonadism. Auxilium is developing additional Testim line extensions, as well as other products for urology and sexual health, including an enzyme in Phase II for the treatment of Peyronie's Disease that may also prove useful for the treatment of Dupuytren's Disease.

Collins Stewart's research department is built around a number of sector-specialist teams. Our analysts are leaders in their area of specialisation and combine deep industry knowledge with decades of stock broking experience to produce insightful, independent sector research. Our research approach encompasses Questâ„¢ principles and focuses on cash-driven valuation techniques. Research is a Collins Stewart cornerstone; it is leveraged throughout the organisation.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/19/2011 8:25 AM Buy
16.84 23.00
as of 12/30/2011
1 Week up  2.20 %
1 Month up  14.34 %
3 Months up  18.34 %
1 YTD up  18.34 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/1/2011 3:25 PM Hold
17.59 23.00
11/5/2010 9:25 AM Hold
21.10 26.00
8/13/2008 9:25 AM Buy
41.29 49.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy